Treats hypertension. ANDA 75269, held by Valeant Pharms North. Nifedipine.
As of Nov 16, 2026, ANDA 75269 (Nifedipine), held by Valeant Pharms North, was first approved by FDA on Dec 4, 2000, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Nifedipine extended-release tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 4, 2000 | Original application | Approved |
| Nifedipine30MG · tablet, extended release;oral | Nifedipine | Rx |
| Nifedipine60MG · tablet, extended release;oral | Nifedipine | Rx |
| Mar 9, 2012 | Supplement 10Labeling | Approved | None posted |
| Dec 16, 2002 | Supplement 6Manufacturing | Approved | None posted |
| Jul 15, 2002 | Supplement 2Manufacturing | Approved | None posted |
| Jul 15, 2002 | Supplement 5Manufacturing | Approved | None posted |
| Feb 14, 2002 | Supplement 1Manufacturing | Approved | None posted |
| Dec 28, 2001 | Supplement 3Manufacturing | Approved | None posted |
| Dec 4, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters